Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
:URGN
Total Valuation
Urogen Pharma has a market cap or net worth of $472.47M. The enterprise value is $419.47M.
Market Cap$472.47M
Enterprise Value$419.47M
Share Statistics
Urogen Pharma has 46.09M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46.09M
Owened by Insiders2.22%
Owened by Instutions47.24%
Financial Efficiency
Urogen Pharma’s return on equity (ROE) is 14.41 and return on invested capital (ROIC) is -41.29%.
Return on Equity (ROE)1441.26%
Return on Assets (ROA)-44.41%
Return on Invested Capital (ROIC)-41.29%
Return on Capital Employed (ROCE)-40.37%
Revenue Per Employee$384,672.34
Profits Per Employee-$539,889.362
Employee Count235
Asset Turnover0.32
Inventory Turnover0.96
Valuation Ratios
The current PE Ratio of Urogen Pharma is -3.60. Urogen Pharma’s PEG ratio is 0.22.
PE Ratio-3.60
PS Ratio5.05
PB Ratio-51.87
Price to Fair Value-51.87
Price to FCF-4.70
Price to Operating Cash Flow-4.72
PEG Ratio0.22
Income Statement
In the last 12 months, Urogen Pharma had revenue of $90.40M and earned -$126.87M in profits. Earnings per share was -$3.30.
Revenue$90.40M
Gross Profit$81.52M
Operating Income-$96.78M
Pretax Income-$124.04M
Net Income-$126.87M
EBITDA-96.31M
Earnings Per Share (EPS)-3.30
Cash Flow
In the last 12 months, operating cash flow was -$96.77M and capital expenditures -$295.00K, giving a free cash flow of -$97.06M billion.
Operating Cash Flow-$96.77M
Free Cash Flow-$97.06M
Free Cash Flow per Share-$2.11
Dividends & Yields
Urogen Pharma pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-21.26%
Earnings Yield-27.78%
Stock Price Statistics
Beta1.29
52-Week Price Change-24.60%
50-Day Moving Average10.70
200-Day Moving Average12.63
Relative Strength Index (RSI)44.41
Average Volume (3m)436.31K
Important Dates
Urogen Pharma upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 10, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Urogen Pharma as a current ratio of 6.01, with Debt / Equity ratio of -14.02
Current Ratio6.01
Quick Ratio5.81
Debt to Market Cap0.27
Net Debt to EBITDA0.44
Interest Coverage Ratio-7.73
Taxes
In the past 12 months, Urogen Pharma has paid $2.83M in taxes.
Income Tax$2.83M
Effective Tax Rate-2.28%
Enterprise Valuation
Urogen Pharma EV to EBITDA ratio is -3.70, with an EV/FCF ratio of -4.20.
EV to Sales4.51
EV to EBITDA-3.70
EV to Free Cash Flow-4.20
EV to Operating Cash Flow-4.22
Balance Sheet
Urogen Pharma has $236.69M in cash and marketable securities with $123.39M in debt, giving a net cash position of -$113.30M billion.
Cash & Marketable Securities$236.69M
Total Debt$123.39M
Net Cash-$113.30M
Net Cash Per Share-$2.46
Tangible Book Value Per Share-$0.21
Margins
Gross margin is 90.18%, with operating margin of -107.06%, and net profit margin of -140.35%.
Gross Margin90.18%
Operating Margin-107.06%
Pretax Margin-137.22%
Net Profit Margin-140.35%
EBITDA Margin-122.05%
EBIT Margin-123.37%
Analyst Forecast
The average price target for Urogen Pharma is $39.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.40
Price Target Upside295.58%
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast9.29%
EPS Growth Forecast13.49%